[
  {
    "ts": null,
    "headline": "RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey",
    "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among […]",
    "url": "https://finnhub.io/api/news?id=d8e4116a23e02004b459202372bfaf298828c4cae4e7580d24d88fd1448d460e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749980322,
      "headline": "RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey",
      "id": 135285025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among […]",
      "url": "https://finnhub.io/api/news?id=d8e4116a23e02004b459202372bfaf298828c4cae4e7580d24d88fd1448d460e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline",
    "summary": "Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=8514212316ee30c4bb7c756206e80d6e18236c12926010e11b6109c275fcc649",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749976289,
      "headline": "Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline",
      "id": 135284904,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202318589/image_1202318589.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=8514212316ee30c4bb7c756206e80d6e18236c12926010e11b6109c275fcc649"
    }
  }
]